What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?
What Are the Factors Affecting Neoadjuvant Chemotherapy Efficacy in Breast Cancer? A Non-invasive in Vivo Study Using Specialist Magnetic Resonance (MR) Methods
Breast cancer is the most prevalent cancer affecting women. To treat locally advanced breast cancers, neoadjuvant chemotherapy (NACT) is often carried out before surgery to reduce the tumour size to allow breast conservation surgery. However, treatment response for individual patients varies, where the tumour may not respond to treatment and the quality of patient care is compromised if the NACT treatment plan is not optimised. Therefore, the assessment of NACT efficacy is beneficial for the early identification of these patients and appropriate management of treatment.
Breast tumours have unique features compared to healthy tissue, including abnormal tissue structure and biochemical composition. With NACT there are specific changes to such tumour features indicating tumour treatment response.
The purpose of this study is to establish how the changes to breast tumour features following NACT treatment are seen in non-invasive imaging. This study will look at scans of breast tumours using magnetic resonance imaging (MRI). Changes to tissue structure will be measured by advanced diffusion MRI techniques and changes to tumour related biochemical substances will be measured by advanced magnetic resonance spectroscopy techniques. The investigators aim to assess if these techniques can provide information on the tumour treatment response following subsequent rounds of NACT treatment.
In this longitudinal study, 25 patients undergoing NACT will be recruited for four repeated MRI investigations over the course of NACT treatment. Magnetic resonance (MR) measurements of tissue microstructure and biochemical composition will be compared against histological measurements and radiological assessments of treatment response.
The study will recruit patients undergoing treatment at the NHS Grampian. This research is funded by Friends of ANCHOR, Tenovus Scotland Grampian and the NHS Grampian Endowment Research Fund.
調査の概要
状態
詳細な説明
In this single group longitudinal study, the investigators propose that functional images from magnetic resonance (MR) methods performed at baseline and after 6 cycles of neoadjuvant chemotherapy (NACT) are in agreement with histological findings from pre-treatment biopsy and post-treatment surgically excised tissue. MR methods will be performed at baseline (pre-treatment) and after the 1st, 3rd and 6th (post-treatment) cycles of NACT treatment. The investigators hypothesise that specific physiological changes detected through MR methods are a manifestation of tumour response to NACT confirmed by histology and radiological assessment (Hypothesis 1). The investigators further hypothesise that early sensitivity to physiological changes manifesting from tumour response to NACT can be revealed by MR measurements after the first and third cycle of treatment (Hypothesis 2).
Research Question 1: Is there a difference in physiological parameters revealed by MR measurements at baseline and after completion of NACT?
Research Question 2: Do the physiological measurements at the completion of NACT from MR measures agree with histological findings?
Research Question 3: Is there a difference between MR measurements at baseline and after the first and third cycle of NACT?
Research Question 4: Is there a difference in MR measurements at baseline, first and third cycle of NACT, between positive treatment responders and non-responders.
MR measurements will be compared against clinical and study specific results from histological analysis and radiological assessment of MRI, mammography and ultrasound measures of tumour treatment response. Information collected from a health questionnaire will supplement interpretation of the data.
To test the effects of NACT on specific aspects of tumour physiology, paired t-tests will be performed on MR measures of lactate concentration, lipid composition and diffusion parameters, between baseline and post-treatment assessments (Research Question 1).
To examine the relationship between MR measurements and histology, correlation analysis will be conducted between baseline and post-treatment assessments. MR measures will be correlated against corresponding percentage changes in histological findings between biopsy and tumour excision (Research Question 2).
To evaluate MR measures as early markers of NACT efficacy, paired t-tests will be carried out between MR measures at pre-treatment and post 1st and 3rd cycles of NACT treatment (Research Question 3), with independent group difference determined between responders and non-responders (Research Question 4).
研究の種類
入学 (予想される)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Aberdeenshire
-
Aberdeen、Aberdeenshire、イギリス、AB25 2ZD
- 募集
- NHS Grampian
-
コンタクト：
- Nicholas Senn, MPhys
- 電話番号：+44 (0)1224 43-8351
- メール：r03ns15@abdn.ac.uk
-
主任研究者：
- Nicholas Senn, MPhys
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Patients with pathologically confirmed invasive breast cancer undergoing neoadjuvant chemotherapy and surgery.
Exclusion Criteria:
- Condition to contradictive to MRI investigation with contrast agent (poor renal function, contrast agent allergy, metal implants or pace maker).
- Started hormone or chemotherapy treatment before recruitment.
- Undergoing treatment for concurrent cancer diagnosis.
- Marker coil contradictive to MRI investigation.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：基礎科学
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Single Arm
25 patients with pathologically confirmed invasive breast cancer who will undergo neoadjuvant chemotherapy treatment (NACT) and surgery will be recruited.
During the study, patients will receive the standard care and the current study will not alter the care plan offered to them.
All patients in the single arm will undergo 4 magnetic resonance imaging scan sessions.
Histopathological analysis will be performed on the core biopsy and tumour tissue removed in surgery.
Health questionnaire will be completed by each patient.
|
Patients will undergo 4 MRI sessions during NACT treatment.
The first scan will take place at treatment baseline before their first cycle of NACT treatment.
The second scan will take place following the first treatment cycle prior to the second treatment cycle.
Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery.
MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.
Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment.
Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.
Health and demographic information will be collected.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Baseline: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
時間枠：Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
The water diffusion probability density function will be quantified by the Full-Width-At-Half-Maximum with units of micrometre
|
Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
|
Post Cycle 1: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
時間枠：Scan at the end of Cycle 1 (Each cycle is 21 days)
|
The water diffusion probability density function will be quantified by the Full-Width-At-Half-Maximum with units of micrometre
|
Scan at the end of Cycle 1 (Each cycle is 21 days)
|
|
Post Cycle 3: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
時間枠：Scan at the end of Cycle 3 (Each cycle is 21 days)
|
The water diffusion probability density function will be quantified by the Full-Width-At-Half-Maximum with units of micrometre
|
Scan at the end of Cycle 3 (Each cycle is 21 days)
|
|
Post Treatment: Water diffusion probability density function (Full-Width-At-Half-Maximum, FWHM, units of micrometre)
時間枠：Scan at the end of Cycle 6 (Each cycle is 21 days)
|
The water diffusion probability density function will be quantified by the Full-Width-At-Half-Maximum with units of micrometre
|
Scan at the end of Cycle 6 (Each cycle is 21 days)
|
|
Baseline: Water diffusivity (units of mm^2 /s)
時間枠：Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
Water diffusivity with units of mm^2 /s
|
Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
|
Post Cycle 1: Water diffusivity (units of mm^2 /s)
時間枠：Scan at the end of Cycle 1 (Each cycle is 21 days)
|
Water diffusivity with units of mm^2 /s
|
Scan at the end of Cycle 1 (Each cycle is 21 days)
|
|
Post Cycle 3: Water diffusivity (units of mm^2 /s)
時間枠：Scan at the end of Cycle 3 (Each cycle is 21 days)
|
Water diffusivity with units of mm^2 /s
|
Scan at the end of Cycle 3 (Each cycle is 21 days)
|
|
Post Treatment: Water diffusivity (units of mm^2 /s)
時間枠：Scan at the end of Cycle 6 (Each cycle is 21 days)
|
Water diffusivity with units of mm^2 /s
|
Scan at the end of Cycle 6 (Each cycle is 21 days)
|
|
Baseline: Lactate Concentration (units of mM)
時間枠：Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
Lactate concentration with units of mM
|
Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
|
Post Cycle 1: Lactate Concentration (units of mM)
時間枠：Scan at the end of Cycle 1 (Each cycle is 21 days)
|
Lactate concentration with units of mM
|
Scan at the end of Cycle 1 (Each cycle is 21 days)
|
|
Post Cycle 3: Lactate Concentration (units of mM)
時間枠：Scan at the end of Cycle 3 (Each cycle is 21 days)
|
Lactate concentration with units of mM
|
Scan at the end of Cycle 3 (Each cycle is 21 days)
|
|
Post Treatment: Lactate Concentration (units of mM)
時間枠：Scan at the end of Cycle 6 (Each cycle is 21 days)
|
Lactate concentration with units of mM
|
Scan at the end of Cycle 6 (Each cycle is 21 days)
|
|
Baseline: Lipid Peak Volume Ratio (Ratio Units)
時間枠：Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
Lipid peak volume ratio value with units of ratio
|
Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
|
Post Cycle 1: Lipid Peak Volume Ratio (Ratio Units)
時間枠：Scan at the end of Cycle 1 (Each cycle is 21 days)
|
Lipid peak volume ratio value with units of ratio
|
Scan at the end of Cycle 1 (Each cycle is 21 days)
|
|
Post Cycle 3: Lipid Peak Volume Ratio (Ratio Units)
時間枠：Scan at the end of Cycle 3 (Each cycle is 21 days)
|
Lipid peak volume ratio value with units of ratio
|
Scan at the end of Cycle 3 (Each cycle is 21 days)
|
|
Post Treatment: Lipid Peak Volume Ratio (Ratio Units)
時間枠：Scan at the end of Cycle 6 (Each cycle is 21 days)
|
Lipid peak volume ratio value with units of ratio
|
Scan at the end of Cycle 6 (Each cycle is 21 days)
|
|
Baseline: Fat Fraction (units of %)
時間枠：Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
Fat Fraction with units of %
|
Scan at pre-treatment baseline (Prior to start of Cycle 1, each cycle is 21 days)
|
|
Post Cycle 1: Fat Fraction (units of %)
時間枠：Scan at the end of Cycle 1 (Each cycle is 21 days)
|
Fat Fraction with units of %
|
Scan at the end of Cycle 1 (Each cycle is 21 days)
|
|
Post Cycle 3: Fat Fraction (units of %)
時間枠：Scan at the end of Cycle 3 (Each cycle is 21 days)
|
Fat Fraction with units of %
|
Scan at the end of Cycle 3 (Each cycle is 21 days)
|
|
Post Treatment: Fat Fraction (units of %)
時間枠：Scan at the end of Cycle 6 (Each cycle is 21 days)
|
Fat Fraction with units of %
|
Scan at the end of Cycle 6 (Each cycle is 21 days)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Core Biopsy Tumour Tissue: Ki-67 Staining Percentage (units of %)
時間枠：Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
Ki-67 staining percentage with units of %, assessed on core biopsy tissue taken prior to start of treatment cycles.
|
Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
|
Excised Tumour Tissue: Ki-67 Staining Percentage (units of %)
時間枠：Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
Ki-67 staining percentage with units of %, assessed on excised tissue taken from surgery following completion of treatment cycles.
|
Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
|
Core Biopsy Tumour Tissue: Serotonin Staining Score (arbitrary units)
時間枠：Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
Serotonin staining score with arbitrary units (multiplication of staining percentage and stain intensity scored 1 - 3), assessed on core biopsy tissue taken prior to start of treatment cycles.
|
Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
|
Excised Tumour Tissue: Serotonin Staining Score (arbitrary units)
時間枠：Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
Serotonin staining score with arbitrary units (multiplication of staining percentage and stain intensity scored 1 - 3), assessed on excised tissue taken from surgery following completion of treatment cycles.
|
Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
|
Core Biopsy Tumour Tissue: Cellularity (units of %)
時間枠：Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
Cellularity with units of %, assessed on core biopsy taken prior to start of treatment cycles.
|
Pre-treatment baseline biopsy (Taken prior to start of Cycle 1, each cycle is 21 days). Assessed following completion of treatment cycles and the routine reporting of core biopsy and excised tissue samples.
|
|
Excised Tumour Tissue: Cellularity (units of %)
時間枠：Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
Cellularity with units of %, assessed on excised tissue taken from surgery following completion of treatment cycles.
|
Post-treatment surgery excision (Post Cycle 6, each cycle is 21 days). Assessed following the completion of routine pathological reporting of the excised tissue.
|
協力者と研究者
スポンサー
協力者
捜査官
- スタディチェア：Jiabao He, PhD、University of Aberdeen
- 主任研究者：Nicholas Senn, MPhys、University of Aberdeen
出版物と役立つリンク
一般刊行物
- Graham LJ, Shupe MP, Schneble EJ, Flynt FL, Clemenshaw MN, Kirkpatrick AD, Gallagher C, Nissan A, Henry L, Stojadinovic A, Peoples GE, Shumway NM. Current approaches and challenges in monitoring treatment responses in breast cancer. J Cancer. 2014 Jan 5;5(1):58-68. doi: 10.7150/jca.7047.
- Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med. 2001 Jul;31(4):269-86. doi: 10.1016/s0010-4825(01)00006-3.
- Lee MC, Newman LA. Management of patients with locally advanced breast cancer. Surg Clin North Am. 2007 Apr;87(2):379-98, ix. doi: 10.1016/j.suc.2007.01.012.
- Luangdilok S, Samarnthai N, Korphaisarn K. Association between Pathological Complete Response and Outcome Following Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer Patients. J Breast Cancer. 2014 Dec;17(4):376-85. doi: 10.4048/jbc.2014.17.4.376. Epub 2014 Dec 26.
- Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed. 2010 Apr;23(3):233-41. doi: 10.1002/nbm.1436.
- Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, Hatabu H, Kan S, Mountford C. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010 Feb;254(2):357-66. doi: 10.1148/radiol.2542090405.
- Walenta S, Mueller-Klieser WF. Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol. 2004 Jul;14(3):267-74. doi: 10.1016/j.semradonc.2004.04.004.
- Carmona-Fontaine C, Bucci V, Akkari L, Deforet M, Joyce JA, Xavier JB. Emergence of spatial structure in the tumor microenvironment due to the Warburg effect. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19402-7. doi: 10.1073/pnas.1311939110. Epub 2013 Nov 11.
- Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med. 2003 Dec;50(6):1134-43. doi: 10.1002/mrm.10654.
- Baik HM, Su MY, Yu H, Mehta R, Nalcioglu O. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA. 2006 May;19(2):96-104. doi: 10.1007/s10334-006-0032-4. Epub 2006 May 9.
- He Q, Shkarin P, Hooley RJ, Lannin DR, Weinreb JC, Bossuyt VI. In vivo MR spectroscopic imaging of polyunsaturated fatty acids (PUFA) in healthy and cancerous breast tissues by selective multiple-quantum coherence transfer (Sel-MQC): a preliminary study. Magn Reson Med. 2007 Dec;58(6):1079-85. doi: 10.1002/mrm.21335.
- Yamada I, Hikishima K, Miyasaka N, Tokairin Y, Ito E, Kawano T, Kobayashi D, Eishi Y, Okano H. Esophageal carcinoma: Evaluation with q-space diffusion-weighted MR imaging ex vivo. Magn Reson Med. 2015 Jun;73(6):2262-73. doi: 10.1002/mrm.25334. Epub 2014 Jun 19.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 2/108/7
- 234794 (その他の識別子：Integrated Research Approval System project ID)
- 17/LO/1777 (その他の識別子：Research Ethics Committee Reference)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。